Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel
NASDAQ:VOR

Vor Biopharma 11/7/2024 Earnings Report

Vor Biopharma logo
$15.90 +0.38 (+2.45%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$15.55 -0.35 (-2.18%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Vor Biopharma EPS Results

Actual EPS
-$8.00
Consensus EPS
-$8.00
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Vor Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vor Biopharma Announcement Details

Quarter
Date
11/7/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Vor Biopharma Earnings Headlines

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 4 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3287173/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by Jefferies Financial Group
May 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30753791
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
 |  American Alternative (Ad)
Vor Biopharma: It's A Game Of Wait And See
April 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4889327-vor-biopharma-its-a-game-of-wait-and-see
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/01/3267042/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Jefferies initiates coverage of Vor Biopharma (VOR) with buy recommendation
March 31, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/jefferies-initiates-coverage-of-vor-biopharma-vor-with-buy-recommendation/ar-AA1ZMSen
See More Vor Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vor Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vor Biopharma and other key companies, straight to your email.

About Vor Biopharma

Vor Biopharma (NASDAQ:VOR), Inc. is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Preclinical studies have demonstrated selective resistance of edited HSCs to CD33-directed therapies, allowing concurrent administration of anti-CD33 agents to eliminate malignant cells while preserving healthy hematopoiesis. In addition to VOR33, Vor maintains a discovery pipeline of follow-on candidates targeting other hematologic cancer antigens, as well as programs exploring combination strategies with existing immunotherapies.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vor Biopharma went public in 2021 and collaborates with leading academic medical centers and contract development organizations across the United States. The company is led by President and Chief Executive Officer Sean Nolan, whose previous experience includes senior leadership roles in immuno-oncology and cell therapy development. Vor’s scientific advisory board comprises experts in hematology, stem cell biology, and genome editing, supporting its mission to transform the treatment paradigm for blood cancer patients.

View Vor Biopharma Profile
Earnings Tools